NCT00869258View on ClinicalTrials.gov

Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Pancreatic Cancer Stage IVA
Interventions
DRUG

Gemcitabine, docetaxel, and capecitabine

Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles

RADIATION

Radiation therapy with gemzar

Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT00869258 - Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar | Biotech Hunter | Biotech Hunter